gsk3191607

GSK3191607 is a novel synthetic small molecule developed by GlaxoSmithKline (GSK) as an inhibitor of the Plasmodium falciparum ATP4 (PfATP4) pathway. It was investigated for its potential as an antimalarial agent. The compound demonstrated inconsistent pharmacokinetic profiles across preclinical species, prompting a human microdose study to assess its clinical pharmacokinetics and support further development decisions. Results from the microdose study indicated a half-life of approximately 17 hours but did not support progression for single-dose cure in malaria due to insufficient efficacy predictions when combined with pharmacodynamic data[1][2][7].

Other names

(S)-N-(2-Fluoropyridin-4-yl)-3-methyl-2-(5-methyl-2,4-dioxo-1,2-dihydropyrido[3,4-d]pyrimidin-3(4H)-yl)butanamide[9]